Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
glomerulonephritis
MeSH D005921 - glomerulonephritis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009393:
Nephritis
0 Companies
0 Drugs
Success rate
D005921:
Glomerulonephritis
54 Companies
15 Drugs
$
Success rate
D005922:
Iga glomerulonephritis
1 Company
1 Drug
$
Success rate
D005923:
Focal segmental glomerulosclerosis
15 Companies
1 Drug
$
Success rate
D008181:
Lupus nephritis
19 Companies
2 Drugs
$
Success rate
D015432:
Membranoproliferative glomerulonephritis
0 Companies
0 Drugs
Success rate
D015433:
Membranous glomerulonephritis
0 Companies
0 Drugs
Success rate
D019867:
Anti-glomerular basement membrane disease
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
33
%
1/3
Phase 2
43
%
9/21
Phase 3
31
%
5/16
Approved:
5
Overall Success rate:
4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Boehringer Ingelheim
Clonidine
Novartis
Chlorthalidone
,
Angiotensin ii
,
Vitamin e
,
Aldosterone
Sanofi
Reserpine
,
Rilzabrutinib
,
SAR442970
Merck & Co
Reserpine
Pfizer
Prazosin
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use